Cargando…
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for l...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111719/ https://www.ncbi.nlm.nih.gov/pubmed/37072770 http://dx.doi.org/10.1186/s12943-023-01770-6 |
_version_ | 1785027505236738048 |
---|---|
author | Li, Bo Chen, Hui Yang, Shaohua Chen, Feng Xu, Liangliang Li, Yan Li, Mingzhe Zhu, Chengming Shao, Fangyuan Zhang, Xinhua Deng, Chuxia Zeng, Leli He, Yulong Zhang, Changhua |
author_facet | Li, Bo Chen, Hui Yang, Shaohua Chen, Feng Xu, Liangliang Li, Yan Li, Mingzhe Zhu, Chengming Shao, Fangyuan Zhang, Xinhua Deng, Chuxia Zeng, Leli He, Yulong Zhang, Changhua |
author_sort | Li, Bo |
collection | PubMed |
description | Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies. |
format | Online Article Text |
id | pubmed-10111719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101117192023-04-19 Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers Li, Bo Chen, Hui Yang, Shaohua Chen, Feng Xu, Liangliang Li, Yan Li, Mingzhe Zhu, Chengming Shao, Fangyuan Zhang, Xinhua Deng, Chuxia Zeng, Leli He, Yulong Zhang, Changhua Mol Cancer Review Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies. BioMed Central 2023-04-18 /pmc/articles/PMC10111719/ /pubmed/37072770 http://dx.doi.org/10.1186/s12943-023-01770-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Li, Bo Chen, Hui Yang, Shaohua Chen, Feng Xu, Liangliang Li, Yan Li, Mingzhe Zhu, Chengming Shao, Fangyuan Zhang, Xinhua Deng, Chuxia Zeng, Leli He, Yulong Zhang, Changhua Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
title | Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
title_full | Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
title_fullStr | Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
title_full_unstemmed | Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
title_short | Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
title_sort | advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111719/ https://www.ncbi.nlm.nih.gov/pubmed/37072770 http://dx.doi.org/10.1186/s12943-023-01770-6 |
work_keys_str_mv | AT libo advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT chenhui advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT yangshaohua advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT chenfeng advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT xuliangliang advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT liyan advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT limingzhe advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT zhuchengming advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT shaofangyuan advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT zhangxinhua advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT dengchuxia advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT zengleli advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT heyulong advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers AT zhangchanghua advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers |